CenterBook Partners LP Reduces Holdings in BioNTech SE Sponsored ADR $BNTX

CenterBook Partners LP reduced its position in shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX) by 14.1% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 185,491 shares of the company’s stock after selling 30,453 shares during the period. BioNTech comprises 0.9% of CenterBook Partners LP’s portfolio, making the stock its 18th largest position. CenterBook Partners LP’s holdings in BioNTech were worth $18,293,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in BNTX. Financial Consulate Inc. purchased a new position in BioNTech in the 3rd quarter valued at about $36,000. Tower Research Capital LLC TRC increased its position in shares of BioNTech by 118.2% during the second quarter. Tower Research Capital LLC TRC now owns 563 shares of the company’s stock worth $60,000 after acquiring an additional 305 shares during the last quarter. Hantz Financial Services Inc. lifted its stake in shares of BioNTech by 472.0% in the second quarter. Hantz Financial Services Inc. now owns 572 shares of the company’s stock worth $61,000 after acquiring an additional 472 shares in the last quarter. GAMMA Investing LLC boosted its holdings in BioNTech by 40.8% in the third quarter. GAMMA Investing LLC now owns 784 shares of the company’s stock valued at $77,000 after purchasing an additional 227 shares during the last quarter. Finally, Rakuten Securities Inc. increased its holdings in BioNTech by 188.1% during the 3rd quarter. Rakuten Securities Inc. now owns 1,043 shares of the company’s stock worth $103,000 after purchasing an additional 681 shares during the last quarter. 15.52% of the stock is owned by institutional investors and hedge funds.

BioNTech Trading Up 1.1%

BioNTech stock opened at $106.99 on Wednesday. BioNTech SE Sponsored ADR has a 52-week low of $81.20 and a 52-week high of $124.49. The company has a quick ratio of 7.02, a current ratio of 7.12 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $24.09 billion, a price-to-earnings ratio of -40.68 and a beta of 1.49. The firm has a 50-day moving average price of $103.34 and a two-hundred day moving average price of $103.48.

Analysts Set New Price Targets

A number of analysts have recently weighed in on BNTX shares. HC Wainwright reissued a “buy” rating and set a $140.00 price target on shares of BioNTech in a research report on Thursday, December 11th. JPMorgan Chase & Co. decreased their price objective on shares of BioNTech from $121.00 to $120.00 and set a “neutral” rating for the company in a report on Thursday, October 23rd. Berenberg Bank reaffirmed a “buy” rating on shares of BioNTech in a research report on Friday, January 23rd. Jefferies Financial Group reiterated a “buy” rating and issued a $151.00 price target on shares of BioNTech in a research note on Wednesday, December 3rd. Finally, Morgan Stanley restated an “overweight” rating and set a $134.00 price objective on shares of BioNTech in a research note on Monday, November 3rd. Eleven investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $140.10.

BioNTech Company Profile

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.